Projects
PD-MIND
A clinical trial to find a potential cure for Parkinson’s Disease. (The trial is continued with other funding.)
Currently there is an unmet clinical need to treat Parkinson disease with mild cognitive impairment (PD-MCI). In fact, nicotinic agonists are specifically relevant for this condition. Hence, the major aim of the project PD-MIND is to identify the potential of the nicotinic α7 agonist AZD0328 in a randomized, placebo-controlled, parallel group, international multicentre study on cognitive function in people diagnosed with PD-MCI.
€ 2.1 M
funding from IMI and EFPIA
9
European Partners
About PD-MIND
PD-MIND’s ambition is to determine the potential effectiveness of a nicotinic receptor agonist on cognitive decline as a primary outcome measure in PD-MCI.
This could be the first systematic evidence of improvement in PD-MCI, an important and widespread condition, inasmuch as the project aims to develop a drug for the first phase 3 clinical trial for PD-MCI. Since PD affects 1% of European citizens over 65 years, this envisioned outcome is expected to have a huge socioeconomic and clinical impact.
Lygature in PD-MIND
Providing multi-disciplinary partnership management, as well as communication and dissemination expertise.
- Program management. Lygature is responsible for the overall management of the PD-MIND project such as ensuring scientific dialogue and communication across the consortium, efficient administration and timely reporting. Moreover, Lygature is responsible for information distribution within the consortium and facilitation of internal communication, a.o. by providing their proprietary “MyProjectPlaza” communication platform. This ensures transparency, efficient clarification and fine-tuning among partners. Lastly, Lygature provides impartial legal advice in various negations during the project.
- Communication and Dissemination. Lygature supports the engagement of important to the project stakeholders by establishing the communication channels through which PD-MIND will effectively interact with its key-stakeholders and support patient recruitment. Lygature will develop the project website and the communications, dissemination and exploitation plan which will contain key instruments for an effective dissemination policy.
Lygature together with
Acknowledgement of support
PD-MIND receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820880. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. See www.imi.europa.eu for more details.
Project updates
-
PD-MIND investigators: Interview with David Hayes
David Hayes represents AstraZeneca and is the industrial co-ordinator of the PD-MIND project.
Read the interview with David here.
-
PD-MIND investigators: Interview with Rebecca Pinto
Dr Rebecca Pinto is a Post-Doctoral researcher and the PD-MIND clinical trial co-ordinator at the Department of Old Age Psychiatry at King’s College London.
Read her interview here. -
PD-MIND investigators: Interview with Herman Verheij
Herman Verheij works as a Program Manager at Lygature in The Netherlands and is responsible for the overall project management of PD-MIND.
Read the interview with Herman here.